Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing Risk Stratification Reduces Patient Burden and Improves Cost-Effectiveness of Hepatocellular Carcinoma Surveillance for People with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Modelling Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

The Prevalence and Risk Factors for at-Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care.

Alimentary pharmacology & therapeutics·2026
Same author

Noninvasive Prediction of Decompensation in Compensated Advanced Chronic Liver Disease and a Liver Stiffness From 15 to 25 kPa.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Metabolic dysfunction-associated fatty liver disease: an update.

Australian prescriber·2026
Same author

Outcomes of first and further decompensation events in advanced chronic liver disease: a multi-centre competing risks analysis.

Hepatology international·2026
Same author

Deprescribing in Older People: A Clinical Practice Guideline Summary.

The Medical journal of Australia·2026

Related Experiment Video

Updated: Jul 12, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Nonalcoholic fatty liver disease.

Leon A Adams1, Keith D Lindor

  • 1School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital Campus, Australia.

Annals of Epidemiology
|August 31, 2007
PubMed
Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common liver condition, often linked to insulin resistance, obesity, and diabetes. Current treatments focus on metabolic factors, but no drug has proven effective in preventing disease progression.

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Internal Medicine

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition in Western societies.
  • It is characterized by hepatic steatosis unrelated to excessive alcohol consumption.
  • Insulin resistance is a key factor in NAFLD pathogenesis, frequently co-occurring with obesity, diabetes, and metabolic syndrome.

Purpose of the Study:

  • To review the current understanding of Nonalcoholic fatty liver disease (NAFLD) pathogenesis, clinical presentation, and management.
  • To highlight the challenges in predicting disease progression and the limitations of current therapeutic strategies.
  • To identify gaps in knowledge regarding the natural history and prognostic factors of NAFLD.

Main Methods:

More Related Videos

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Jul 12, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

  • Literature review of studies on Nonalcoholic fatty liver disease (NAFLD) epidemiology, pathophysiology, and treatment.
  • Analysis of risk factors associated with advanced liver disease and hepatocellular carcinoma.
  • Evaluation of clinical trial data for insulin-sensitizing and hepatoprotective agents.

    • Main Results:

    • Nonalcoholic fatty liver disease (NAFLD) affects a significant portion of the Western population, often asymptomatic but potentially leading to cirrhosis and liver cancer.
    • While diabetes, obesity, and age are known risk factors for advanced NAFLD, other contributing factors remain unidentified.
    • Current treatments primarily target metabolic risk factors, with no specific agent demonstrating conclusive efficacy in halting disease progression.

    Conclusions:

    • Effective prediction of which patients will develop progressive liver injury and benefit from treatment remains a significant clinical challenge.
    • Further research is needed to elucidate the natural history of Nonalcoholic fatty liver disease (NAFLD) and identify novel therapeutic targets.
    • Management strategies require improvement to address the growing burden of this metabolic liver disease.